Basso U - Search Results

1

Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study.

Brandes AA, Ermani M, Basso U, Amistà P, Berti F, Scienza R, Rotilio A, Pinna G, Gardiman M, Monfardini S. Brandes AA, et al. Among authors: basso u. Ann Oncol. 2001 Feb;12(2):255-7. doi: 10.1023/a:1008336732273. Ann Oncol. 2001. PMID: 11300334 Free article. Clinical Trial.

2

High-dose chemotherapy with bone marrow rescue for high-grade gliomas in adults.

Brandes AA, Palmisano V, Pasetto LM, Basso U, Monfardini S. Brandes AA, et al. Among authors: basso u. Cancer Invest. 2001;19(1):41-8. doi: 10.1081/cnv-100000084. Cancer Invest. 2001. PMID: 11291555 Review.

3

New strategy developments in brain tumor therapy.

Brandes AA, Basso U, Pasetto LM, Ermani M. Brandes AA, et al. Among authors: basso u. Curr Pharm Des. 2001 Nov;7(16):1553-80. doi: 10.2174/1381612013397221. Curr Pharm Des. 2001. PMID: 11562299 Review.

4

Predictive value of different prognostic factors in breast cancer recurrences: multivariate analysis using a logistic regression model.

Lumachi F, Ermani M, Brandes AA, Basso S, Basso U, Boccagni P. Lumachi F, et al. Among authors: basso s, basso u. Anticancer Res. 2001 Nov-Dec;21(6A):4105-8. Anticancer Res. 2001. PMID: 11911301

5

Temozolomide in glioblastoma multiforme of the elderly.

Brandes AA, Vastola F, Basso U, Pasetto LM, Ermani M, Berti F, Rotilio A, Amistà P, Scienza R, Monfardini S. Brandes AA, et al. Among authors: basso u. Tumori. 2002 Jan-Feb;88(1 Suppl 1):S69-70. doi: 10.1177/030089160208800120. Tumori. 2002. PMID: 11989929 Clinical Trial. No abstract available.

6

A multidrug combination designed for reversing resistance to BCNU in glioblastoma multiforme.

Brandes AA, Turazzi S, Basso U, Pasetto LM, Guglielmi B, Volpin L, Iuzzolino P, Amistà P, Pinna G, Scienza R, Ermani M. Brandes AA, et al. Among authors: basso u. Neurology. 2002 Jun 25;58(12):1759-64. doi: 10.1212/wnl.58.12.1759. Neurology. 2002. PMID: 12084873 Clinical Trial.

7

Diagnostic advances and new trends for the treatment of primary central nervous system lymphoma.

Basso U, Brandes AA. Basso U, et al. Eur J Cancer. 2002 Jul;38(10):1298-312. doi: 10.1016/s0959-8049(02)00031-x. Eur J Cancer. 2002. PMID: 12091059 Review.

8

Changing boundaries in the treatment of malignant gliomas.

Brandes AA, Basso U, Pasetto LM. Brandes AA, et al. Among authors: basso u. Expert Rev Anticancer Ther. 2001 Oct;1(3):357-70. doi: 10.1586/14737140.1.3.357. Expert Rev Anticancer Ther. 2001. PMID: 12113103 Review.

9

Non-cytotoxic therapies for malignant gliomas.

Basso U, Ermani M, Vastola F, Brandes AA. Basso U, et al. J Neurooncol. 2002 May;58(1):57-69. doi: 10.1023/a:1015839111005. J Neurooncol. 2002. PMID: 12160142 Review.

10

Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study.

Brandes AA, Ermani M, Basso U, Paris MK, Lumachi F, Berti F, Amistà P, Gardiman M, Iuzzolino P, Turazzi S, Monfardini S. Brandes AA, et al. Among authors: basso u. Oncology. 2002;63(1):38-41. doi: 10.1159/000065718. Oncology. 2002. PMID: 12187069 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

262 results

Search Page

Filters